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Abstract
Background: It has been hypothesised that increased VEGF-D expression may be an independent prognostic factor 
for endometrial cancer progression and lymph node metastasis; however, the mechanism by which VEGF-D may 
promote disease progression in women with endometrial cancer has not been investigated. Our aim was to describe 
the distribution of lymphatic vessels in mouse uterus and to examine the effect of VEGF-D over-expression on these 
vessels in a model of endometrial cancer. We hypothesised that VEGF-D over-expression would stimulate growth of 
new lymphatic vessels into the endometrium, thereby contributing to cancer progression.
Methods: We initially described the distribution of lymphatic vessels (Lyve-1, podoplanin, VEGFR-3) and VEGF-D 
expression in the mouse uterus during the estrous cycle, early pregnancy and in response to estradiol-17beta and 
progesterone using immunohistochemistry. We also examined the effects of VEGF-D over-expression on uterine 
vasculature by inoculating uterine horns in NOD SCID mice with control or VEGF-D-expressing 293EBNA tumor cells.
Results: Lymphatic vessels positive for the lymphatic endothelial cell markers Lyve-1, podoplanin and VEGFR-3 profiles 
were largely restricted to the connective tissue between the myometrial circular and longitudinal muscle layers; very 
few lymphatic vessel profiles were observed in the endometrium. VEGF-D immunostaining was present in all uterine 
compartments (epithelium, stroma, myometrium), although expression was generally low. VEGF-D immunoexpression 
was slightly but significantly higher in estrus relative to diestrus; and in estradiol-17beta treated mice relative to vehicle 
or progesterone treated mice. The presence of VEGF-D over-expressing tumor cells did not induce endometrial 
lymphangiogenesis, although changes were observed in existing vessel profiles. For myometrial lymphatic and 
endometrial blood vessels, the percentage of profiles containing proliferating endothelial cells, and the cross sectional 
area of vessel profiles were significantly increased in response to VEGF-D in comparison to control tumor cells. In 
contrast, no significant changes were noted in myometrial blood vessels. In addition, examples of invading cells or 
tumor emboli were observed in mice receiving VEGF-D expressing 293EBNA cells.
Conclusions: These results illustrate that VEGF-D over-expression has differential effects on the uterine vasculature. 
These effects may facilitate VEGF-D's ability to promote endometrial cancer metastasis and disease progression.
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To date, minimal research has been directed at elucidat-
ing the mechanisms responsible for normal and abnormal
growth and development of the endometrial lymphatic
vasculature [1-3]. This is despite the hypothesised or
known role for this vascular system in various gynaeco-
logical pathologies, including endometrial cancer. We
recently used a specific marker of lymphatic endothelial
cells (podoplanin [D2-40]) to describe the distribution of
lymphatic vessels within the human uterus [4]. Lymphatic
vessels were observed in both the myometrium and endo-
metrium, with fewer vessels present in the endometrial
functionalis compared to the basalis. In endometrial ade-
nocarcinoma, significant increases in vessel density were
observed in the peri-tumoral relative to normal basalis
and myometrium. Vascular space invasion was also
observed, with the vessels affected exhibiting a mixed
lymphatic and blood endothelial cell phenotype [4]. In
other studies of endometrial cancer, increased peri-
tumoral lymphatic vessel density was a marker of higher
grade endometrial tumours with a less favourable prog-
nosis [5,6]. The presence of vascular space invasion has
also been reported to be a strong predictor of lymph node
metastasis, disease recurrence and poor prognosis [7-10].
In combination, these studies highlight the importance of
the uterine lymphatic vasculature to endometrial cancer
progression. However, the specific features of endome-
trial tumour cells that promote this dissemination are not
well understood.
A growth factor involved in both angiogenesis and
lymphangiogenesis is vascular endothelial growth factor
(VEGF)-D. VEGF-D, and the related protein VEGF-C, are
initially produced as full-length forms, which can be
enzymatically cleaved to generate smaller polypeptides or
isoforms with enhanced receptor binding affinities [11-
19]; various isoforms of both growth factors are present
within the human endometrium [4]. In humans, the
mature and fully processed forms of VEGF-C and VEGF-
D bind and activate VEGF receptor-2 (VEGFR-2) and
VEGFR-3, which are found predominately on blood and
lymphatic endothelial cells, respectively [20]. {Note:
Mouse VEGF-D does not interact with mouse VEGFR-2.
[21]} VEGF-D deficient mice lack an overt phenotype and
have normal vasculature and fertility, suggesting that
embryonic lymphangiogenesis is not dependent on
VEGF-D [22,23]. However, several studies have shown
that VEGF-D stimulates lymphangiogenesis and/or
angiogenesis in vivo in the adult [24,25].
Increased VEGF-D expression has been observed in
several reproductive tract cancers in association with
lymph node metastases [26]. In endometrial adenocarci-
noma, increased VEGF-D protein expression was
observed in tumour relative to normal cycling endome-
trium [4]. Increased VEGF-D expression has also been
reported to be an independent prognostic factor for
endometrial cancer progression and may predict myome-
trial invasion and lymph node metastasis [27].
Previous studies have demonstrated a tissue-specific
effect of VEGF-D on vascular remodeling. In this study,
our aim was to determine the response of uterine vascu-
lature to VEGF-D expressing cells in a mouse model of
endometrial cancer. In the first instance, we described the
distribution of lymphatic vessels in the mouse uterus
using the lymphatic endothelial cell markers lymphatic
endothelial hyaluronan receptor 1 (Lyve-1), podoplanin
and VEGF receptor-3 (VEGFR-3). Lymphatic vessels pos-
itive for the above markers were largely restricted to the
myometrium with few vessels present in the endome-
trium. We hypothesised that VEGF-D over-expression
would stimulate growth of new lymphatic vessels into the
endometrium. Interestingly, endometrial lymphangio-
genesis did not occur in response to VEGF-D over-
expression; however, enlargement and proliferation of
existing endometrial blood and myometrial lymphatic
vessels was observed. In addition, tumour cells were also
observed within lymphatic vessel profiles.
Methods
Animals
All mice were housed under controlled environmental
conditions (20°C, 12 h light per day) and provided with
food and water ad libitum. Animal studies were approved
by the Monash Medical Centre Animal Ethics Committee
A.
Distribution of lymphatic vessels and VEGF-D expression in 
the mouse uterus
Uterine tissues were collected from C57BL/6J × CBA
mice (7-13 weeks, 18-28 g, Monash Animal Services,
Monash University, Victoria, Australia) at different stages
of the estrous cycle (diestrus, proestrus and estrus; n = 7-
9), during early pregnancy (days 1-4, n = 4-5) and follow-
ing treatment with both exogenous estradiol-17β and
progesterone (as per published protocols [28-31]. Anaes-
thetized mice were bilaterally ovariectomized and left for
7 days following ovariectomy. One group of mice was
treated with a single s.c. injection of estradiol-17β (100 ng
in 100 μl peanut oil), followed by a no-treatment day and
three consecutive daily s.c. injections of progesterone (1
mg in 100 μl peanut oil), before dissection 24 h after the
final hormone injection (n = 8) [28,31]. Other groups
were injected with the vehicle (100 μl peanut oil, n = 7),
or progesterone injections only (n = 7). A final group of
ovariectomised mice received a single s.c. injection of
estradiol-17β (100 ng in 100 μl peanut oil) and was dis-
sected 24 h later (n = 7) [29,30]). All uterine tissues were
removed and immersion fixed in 10% buffered formalin
for 2 h before processing prior to immunohistochemistry
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activity.
VEGF-D overexpression in the mouse uterus
Preparation of tumor cells
Two cell lines were used: human embryonic kidney
293EBNA (Epstein-Barr virus nuclear antigen) and
293EBNA-VEGF-D cells. The latter cell line is stably
transfected with an expression construct encoding full-
length human VEGF-D Flag tagged at the C-terminus, as
previously described [19], and has been shown to induce
lymphangiogenesis in another model [25]. 293EBNA cells
were chosen for the current study as they are a well char-
acterized cell line that does not express detectable levels
of VEGF-A, VEGF-C or VEGF-D [25]. This allows the
specific effects of VEGF-D to be investigated without the
confounding effects of other VEGF family members. Both
cell lines were maintained in culture (DMEM/F12, Invit-
rogen; Melbourne, Australia) with 10% fetal calf serum
(CSL; Melbourne, Australia), antibiotics and glutamine
(Invitrogen; Melbourne, Australia) under normoxic con-
ditions (5% CO2 and air). The VEGF-D-expressing cells
were cultured in the presence of hygromycin B (100 μg/
ml: Invitrogen) as the VEGF-D expression vector encodes
the resistance gene for this antibiotic.
Uterine inoculation with tumor cells
Uteri from normal cycling NOD/SCID (Non-Obese Dia-
betic/Severe Combined Immunodeficiency) mice were
inoculated with tumor cells following a procedure
adapted from Hashii et al. [32]. One group of animals
received 293EBNA cells (n = 9) and a second group
received 293EBNA-VEGF-D cells (n = 9). Following
anaesthesia with Ketamine and Xylazine (100 mg/kg and
5 mg/kg respectively), a 5% agar plug was inserted into
the vagina of each mouse to prevent leakage of injected
cells. The upper region of a uterine horn was then exteri-
orized through a small incision in the lower ventral
region, just below the kidney. Before the injection, surgi-
cal thread (Coated Vicryl, Johnson and Johnson, Austra-
lia) was placed around the upper region of the horn near
the oviduct. A needle was inserted into the upper region
of the uterine horn and the inner region of the horn then
damaged by scraping with a 25 gauge needle. A syringe
containing 5 × 106 cells in 50 μl media was attached to the
needle and the cells injected. The surgical thread was
then tied off to prevent backflow of the injected cells. The
second uterine horn received an intramuscular injection
of a similar cell mix. A 25 gauge needle was inserted along
the outer muscular wall of the upper region of the uterus
near the oviduct. The injection site was then ligatured to
prevent backflow.
NOD SCID mice were left for period of 4 weeks to
allow tumors to form. After 4 weeks, the uterine tissue
was collected from each animal and formalin fixed for
histological examination. Each horn was separated into
an upper region (including the ovary, ligature and upper
uterine horn; including injection site) and a lower distal
region (including the lower uterine horn and cervical
junction; away from injection site). Uterine samples were
orientated longitudinally and blocked in paraffin.
Immunohistochemistry
Antibodies against Lyve-1 (polyclonal goat anti-human
Lyve-1, 1 μg/ml; #AF2089, R&D, Minneapolis, MN,
USA), podoplanin (goat anti-mouse podoplanin, 1 μg/ml,
#AF3244, R&D) and VEGFR-3 (monoclonal rat anti
VEGFR-3, 2 μg/ml; clone AFL4, now commercially avail-
able from R&D Systems) were used to identify lymphatic
vessels. Blood vessels were identified using CD31 (rat anti
mouse CD31, 5 μg/ml; #553370, BD Pharmingen, Frank-
lin Lakes, NJ, USA). When required, dual immunostain-
ing was used to illustrate blood (CD31) versus lymphatic
(podoplanin) vessel distribution and to identify prolifer-
ating cells (monoclonal mouse anti-proliferating cell
nuclei antibody {PCNA}, 1 μg/ml, NCL-PCNA, Novacas-
tra Laboratories, Newcastle, United Kingdom) in lym-
phatic or blood vessels. Mouse VEGF-D was detected
using a polyclonal goat anti-mouse VEGF-D antibody (1
μg/ml, #AF469, R&D). An antibody directed specifically
against human VEGF-D (monoclonal mouse anti-human
VEGF-D, 5 μg/ml, #MAB286, R&D) was used to identify
293EBNA cells transfected with VEGF-D within mouse
tissues. An antibody directed against human mitochon-
drial antigen was used to identify non-transfected
293EBNA cells (monoclonal mouse anti-human mito-
chondria, 250 μg/ml, MAB1273, Chemicon, Temecula,
CA, USA; does not cross react with mouse antigens).
Following dewaxing and rehydration, antigen retrieval
was performed by incubating sections (3 or 5 μm) in 0.1%
(1 mg/ml) pepsin in 3% acetic acid (10 min, 37°C) (for
CD31 staining) or by microwaving sections in tri-sodium
citrate buffer (for all other antibodies) (10 nM Na-Citrate,
pH6). For all protocols except VEGFR-3, sections were
then incubated with H2O2 (3% dH2O2, 47% H2O, 50%
methanol, 10 min) to quench endogenous peroxidase and
protein blocking solution (PBA, Immunon Shandon, PA,
USA) to prevent non-specific binding. For immunostain-
ing of VEGFR-3, the endogenous peroxidase was
quenched using 0.2% NaN3/0.6% H2O2 in methanol (30
min) followed by PBA. Following incubation with pri-
mary antibodies (1 h at 37°c or overnight at 4°C), a bioti-
nylated secondary antibody was applied (Lyve-1: ready to
use biotinylated rabbit anti-goat IgG, 15 min, #50-232Z,
Zymed, San Francisco, CA, USA, VEGFR-3 and CD31:
biotinylated goat anti-rat IgG, 1:200 for 1 hour, #AP183B,
Chemicon; podoplanin: biotinylated rabbit anti-goat IgG,
30 min, A10518, Invitrogen, Carlsbad, CA, USA, mouse
VEGF-D: biotinylated rabbit anti-goat, 1:200 for 30 min,
Girling et al. Reproductive Biology and Endocrinology 2010, 8:84
http://www.rbej.com/content/8/1/84
Page 4 of 14#81-1644, Zymed; human VEGF-D: mouse on Mouse
(MOM) kit, #BMK-2202, Vector Laboratories, Burl-
ingame, USA, human cells: LSAB2 System-HRP, DakoCy-
tomation, Carpinteria, CA, USA; PCNA: EnVision+
System-HRP (AEC), DakoCytomation).
Immunostaining for Lyve-1, VEGFR-3, VEGF-C,
mouse VEGF-D and human mitochondrial antigen was
visualized after incubation in LSAB2 streptavidin-HRP
(DakoCytomation) for 15 min followed by the chromogen
3,30-diaminobenzidine (DAB) (Sigma-Aldrich). Immu-
nostaining for CD31 and Lyve-1 (note that two different
protocols were used for Lyve-1 immunostaining making
use of DAB or vector blue as appropriate) was visualized
after incubation with LSAB2 streptavidin-AP (15 min,
DakoCytomation) followed by vector blue chromogen (10
min, Vector Laboratories, CA, USA). Immunostaining for
podoplanin was visualized after incubation with the
Vectastain ABC kit (Vector Labs Inc, Burlingame, CA)
for 10 min followed by DAB. Immunostaining for human
VEGF-D was performed using the mouse on mouse
(MOM) kit according to manufacturer's instructions
(VECTOR Laboratories, Burlingame, USA) and was visu-
alized with DAB (Sigma-Aldrich).
When dual immunostaining was used to detect CD31
and podoplanin, the CD31 protocol outlined above was
conducted first, followed by the podoplanin protocol.
When dual immunostaining for PCNA and either CD31
or Lyve-1, immunostaining for the endothelial cell-spe-
cific antibody was conducted first, followed by immunos-
taining with the primary antibody against PCNA. PCNA
immunostaining was visualized with Envision (Dakocyto-
mation) followed by aminoethyl carbazole (AEC)
(Zymed, CA, USA).
For each protocol, a negative isotype matched control
was prepared by replacing the primary antibodies with
the appropriate matched IgG at the same concentrations
as those of the primary antibodies.
Image analysis
All image analysis was performed using the Analytical
Imaging System (AIS 30, Rev 1.7; Imaging Research Inc.,
GE Healthcare Bio-Sciences, Rydalmere, NSW, Austra-
lia).
A qualitative description of the distribution of lymphat-
ics in the mouse uterus was made. Following VEGF-D
overexpression, lymphatic (LVD) and blood (BVD) vessel
density was determined in both the myometrium and
endometrium (BVD only) at sites near (approximately
600 μm) and distal (lower uterine region) to the tumors.
Sections were scanned at low magnification to determine
areas of high vessel density. Blood and lymphatic vessel
profiles were then counted from four fields of view using
a ×20 objective lens and the mean vessel density estab-
lished per mm2.
PCNA positive and negative vessels were counted in
the same areas and a proliferation index calculated (per-
centage of vessel profiles containing ≥ 1 proliferating
cells). The cross-sectional area of the five largest lym-
phatic vessel and blood vessel profiles located near and
distal to the tumor (as described above) within the myo-
metrium and endometrium were also measured.
Statistics
Statistical analysis was performed using SPSS for Win-
dows, version 14.0 (SPSS Inc., Chicago, IL, USA). A p-
value less than 0.05 was considered significant. Measure-
ments are presented as mean values ± SEM.
Two-way ANOVAs were used to compare the mean
values for vessel density, proliferation and vessel size in
relation to cell type (for VEGF-D expressing and control
cells) and proximity to tumor (near and distal). If signifi-
cant differences were found, Tukey HSD post hoc analysis
was performed.
Results
Lymphatic vessels are largely restricted to the myometrium 
in mouse uterus
To determine the distribution of lymphatic vessels in the
mouse uterus, we initially examined Lyve-1 immunoreac-
tivity in uterine sections from mice across the estrus
cycle, during early pregnancy and in response to estrogen
and progesterone treatment. Lyve-1-positive lymphatic
vessels were almost exclusively observed in the connec-
tive tissue or stroma between the longitudinal and circu-
lar muscle layers of the myometrium (Figure 1).
Lymphatic vessel profiles were also observed between the
muscle bundles. [Potential differences in number and size
of lymphatic vessels within the myometrium among dif-
ferent treatment groups have not been quantified in the
current study.]
In contrast to the myometrium, Lyve-1 lymphatic vessel
profiles were extremely rare within the endometrium.
Lymphatic vessels were only observed on 17% (14 of 81
sections examined, 1-2 section per mouse) of the Lyve-1
immunostained sections examined (not specific to any
particular treatment group). When lymphatic vessel pro-
files were observed, the sections usually contained only 1-
2 profiles, which were nearly always situated directly
adjacent to the endometrial/myometrial border.
In previous human studies using Lvye-1 immunostain-
ing, lymphatic vessels were only detected within the myo-
metrium, but not the endometrium [33,34]. To determine
whether a population of Lyve-1 negative lymphatic ves-
sels are also present in the mouse endometrium, we
immunostained a subset of sections with antibodies
against podoplanin and VEGFR-3.
As with Lyve-1, podoplanin-positive lymphatic vessels
were observed predominately in the mouse myometrium
Girling et al. Reproductive Biology and Endocrinology 2010, 8:84
http://www.rbej.com/content/8/1/84
Page 5 of 14(Figure 1A-B). Podoplanin immunoreactivity was also
observed in the connective tissues surrounding the vas-
cular smooth muscle cells of arterioles within the myo-
metrium and sometimes in the basal regions of the
endometrium. Additionally, non-vascular immunostain-
ing was observed to varying degrees in the stromal fibro-
blasts in the basal region of the endometrium lying
adjacent to the myometrium. No podoplanin immunos-
taining was observed in the sub-epithelial regions of the
endometrium.
The VEGFR-3 antibody was not useful as a specific
lymphatic vessel marker in mouse uterus (Figure 1D).
Although the myometrial lymphatic vessels were VEGFR-
3 positive, there was also varying amounts of VEGFR-3
immunoreactivity in other uterine components including
the myometrium, stroma, epithelium and blood vessels.
The immunostaining did not relate to a particular repro-
ductive state. In other sections, individual cells within the
endometrium labelled intensely with the VEGFR-3 anti-
Figure 1 Lymphatic vessels are largely restricted to the myometrium in mouse uterus. (A) Representative photomicrograph of podoplanin 
(brown) and CD31 (blue) dual-immunostaining in mouse uterus highlighting the lymphatic and blood vessels, respectively. An area of a transverse 
section is shown. (B) Higher magnification of tissue within boxed area in A. Note the pale but distinct non-lymphatic podoplanin immunoreactivity in 
the connective tissue around the myometrial arteriole (white arrow). (C) Lyve-1 immunostaining is also useful for identifying uterine lymphatic vessels, 
as seen in this photomicrograph from a section serial to that in B. (D) VEGFR-3 immunostaining in a section serial to that in C (Inset: isotype-matched 
control for VEGFR-3). VEGFR-3 immunoreactivity is not useful as a marker of uterine lymphatics as varying levels of immunostaining are also observed 
in other uterine cellular components. (E, F) Representative photomicrographs of human VEGF-D (brown)/Lyve-1 (blue) and (G, H) VEGFR-3 immunos-
taining in NOD SCID mouse uterus inoculated with VEGF-D expressing 293EBNA cells. Note: F and H are higher magnification images of tissue within 
boxed area in E and G, respectively. Black arrows: lymphatic vessels. Dotted line delineates myometrium and endometrium. en: endometrium, m: my-
ometrium, t: tumor.
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analyses were conducted with the Lyve-1 antibody.
VEGF-D is expressed by the mouse uterus
VEGF-D immunoreactivity was analysed in uteri col-
lected from mice during the estrous cycle, in early preg-
nancy and following estrogen or progesterone treatment.
VEGF-D immunostaining was observed in all uterine
compartments (luminal epithelium, glandular epithelium,
endometrial stroma and myometrium) in all sections
examined, although VEGF-D immunostaining was gener-
ally low (Figure 2).
VEGF-D immunostaining varied significantly during
the estrous cycle (F(2,92) = 9.6, p = 0.02); immunostaining
was slightly but significantly more intense during estrus
in comparison to diestrus (Figure 2D). VEGF-D immu-
nostaining also varied significantly among the different
uterine regions in mice collected at different stages of the
estrous cycle (F(3,92) = 9.6, p < 0.001), with immunostain-
ing significantly less intense in the stroma in comparison
to the other regions examined.
VEGF-D immunostaining did not vary significantly
across the first 4 days of pregnancy (F(3,56) = 2.2, p = 0.1,
Figure 2E), although immunostaining did vary among the
different uterine regions (VEGF-D: F(3,56) = 4.2, p < 0.001).
VEGF-D immunostaining was significantly higher in the
luminal and glandular epithelium in comparison to the
stroma and myometrium.
VEGF-D immunostaining in ovariectomised mouse
uterus varied significantly in response to exogenous hor-
mone treatment (F(3,116) = 6.0, p = 0.001, Figure 2F).
Immunostaining also varied among the different uterine
compartments (VEGF-D: F(3,116) = 4.9, p = 0.003). Estra-
diol-17β treated animals had slightly, but significantly,
higher VEGF-D immunostaining than mice treated with
vehicle or progesterone (with or without estradiol-17β
priming); this was particularly apparent in the luminal
and glandular epithelium.
Effects on the uterine vasculature in a mouse model of 
VEGF-D over-expression
To determine the response of the uterus to pathological
over-expression of the VEGF-D polypeptide, we devel-
oped a mouse model in which the human 293EBNA line
expressing VEGF-D was grown as a xenograft in the
uterus of NOD/SCID mice. This is a model adapted from
the skin tumor model previously published by some of us
[25]. Tumors developed in all mice inoculated with either
control 293EBNA cells (n = 9) or 293EBNA-VEGF-D cells
(n = 9), either within or adjacent to (on mesometrium)
the uterus. However, only uteri from mice that had
tumors within the uterus (endometrium and/or myome-
trium) were analysed (uteri near tumors from mice
receiving control 293EBNA cells: n = 9; uteri near tumors
from mice receiving 293EBNA-VEGF-D cells: n = 7).
Pieces of uteri lacking tumor were also collected from
sites distal to the site of tumor cell injection (lower uter-
ine horn). VEGF-D production by 293EBNA-VEGF-D
cells within the mouse uterus was confirmed by immuno-
histochemistry. However, it was not possible to quantify
VEGF-D production in the current model because of the
variable number and distribution of cells within uterine
tissues. Bioactivity of the VEGF-D produced by
293EBNA-VEGF-D cells has previously been confirmed
by mitogenesis and miles assays [25].
Over-expression of VEGF-D did not stimulate endometrial 
lymphangiogenesis
We used antibodies directed against Lyve-1 to examine
the mouse uterine vasculature in response to over-
expression of VEGF-D. As with the above observations,
lymphatic vessels were almost exclusively located
between the circular and longitudinal muscular layers of
the uterine horn and occasionally adjacent to the endo-
metrial-myometrial junction in NOD/SCID mice. No
endometrial lymphatic vessels were observed in any of
the samples analyzed from mice receiving either tumor
cell type (n = 0/16). Uteri were also immunostained with
an antibody directed against VEGFR-3. However, as
noted in C57/CBA mice, immunostaining was not
restricted to lymphatic vessels (contrast Figure 1E-F with
Figure 1G-H). Although lymphatic vessels stained, low
immunoreactivity was also noted in other uterine tissues
including blood vessels. Therefore, Lyve-1 was used for
analyses. VEGFR-3 immunoreactivity in tumor cells was
negligible or absent (Figure 1G).
VEGF-D over-expression caused proliferation and 
enlargement of existing myometrial lymphatic vessels
There was no significant difference in myometrial lym-
phatic density (LVD) between mice with 293EBNA-
VEGF-D tumors versus control tumors (cell type: F(1,32) =
0.08, p = 0.78). However, LVD was significantly reduced
near 293EBNA-VEGF-D tumors versus sites distal from
293EBNA-VEGF-D tumors (p = 0.04). This reduction in
LVD was not observed in mice with control tumors (p =
0.68; Figure 3A).
In contrast to LVD, both the amount of endothelial cell
proliferation (F(1,32) = 4.32, p = 0.047, Figure 3B, 4A and
4B) and the vessel cross sectional areas (F(1,32) = 17.4, p <
0.001, Figure 3C, 4C and 4D) were significantly affected
by VEGF-D over expression. Post hoc analysis confirmed
that both variables were significantly increased near the
293EBNA-VEGF-D tumors when compared to that near
the control tumors and distal to both tumor types. The
increase in endothelial cell proliferation may contribute
to the increase in lymphatic vessel size.
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proliferation of endometrial, but not myometrial blood 
vessels
The presence of 293EBNA tumor cells caused a similar
response in the endometrial blood vessels as was
observed in the myometrial lymphatic vessels described
above. There was no significant difference between endo-
metrial BVD at sites either near or distal to 293EBNA-
VEGF-D compared to control tumors (Figure 5A). VEGF-
D over-expression caused significant changes in endome-
trial blood vessel proliferation (F(1,32) = 5.36, p = 0.028,
Figure 4E, F and 5B) and the cross sectional area of ves-
sels (F(1,32) = 23.77, p < 0.001, Figure 4G, H and 5C). The
percentage of proliferating blood vessels and the area of
blood vessels near 293EBNA-VEGF-D tumors was signif-
icantly increased compared to near control tumors and
distal to the both tumor types.
The changes observed in the myometrial lymphatics
and the endometrial blood vessels were not observed in
the myometrial blood vessels. There was no change in
Figure 2 VEGF-D immunostaining in the mouse uterus. Representative photomicrographs (A-C) and semi-quantitative evaluation (D-F) of VEGF-
D immunostaining in the mouse uterus. Representative photomicrographs from a normal cycling (estrous cycle) mouse (A), from a mouse in the early 
pregnancy (pre-implantation (B), and from an ovariectomised mouse (C). Inset in (A): isotyped-matched control. Ep: luminal epithelium, G: gland, M: 
myometrium, S: endometrial stroma. Semi-quantitative evaluation of VEGF-D (D-F) immunostaining in luminal epithelium, glandular epithelium, en-
dometrial stroma and myometrium from the uterus of mice during the estrous cycle (D, n = 7-9), early pregnancy (E, days 1-4, n = 4-5) and in ovariec-
tomised mice (F) following vehicle (n = 7), estradiol-17β (E × 24 h, n = 7), progesterone (P, n = 7), or progesterone following estradiol-17β priming (E 
+ P, n = 8). Data are illustrated as means ± SEM. Groups that do not share a letter in common are significantly different (P < 0.05)
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trial blood vessels containing proliferating endothelial
cells (Figure 6B), or the surface area of myometrial blood
vessels (Figure 6C).
VEGF-D tumor cells were observed in myometrial lymphatic 
vessels
A common feature of endometrial cancer is vascular
space invasion by tumor cells. In the current study, none
of the control tumor cells had invaded the myometrial
lymphatic vessels (n = 0/9), while examples of myometrial
lymphatic vessels containing invading cells or tumor
emboli were observed in all uteri receiving 293EBNA-
VEGF-D cells (n = 7/7) (Figure 7). Similar invasion in
blood vessels was not observed.
Discussion
We have shown that lymphatic vessels positive for the key
lymphatic endothelial cell markers Lyve-1, podoplanin
and VEGFR-3 are largely restricted to the connective tis-
sue between the longitudinal and circular layers of the
myometrium in the mouse uterus; only very few lym-
phatic vessels were present within the mouse endome-
trium and when observed were nearly always situated
adjacent to the myometrial-endometrial border. We have
also demonstrated that the presence of tumor cells over-
expressing human VEGF-D has differential effects on the
uterine vasculature in a mouse model of endometrial can-
cer. Unexpectedly, 293EBNA cells expressing human
VEGF-D did not stimulate growth of new (lyve-1 posi-
tive) lymphatic vessels into the mouse endometrium,
although they did stimulate changes in the pre-existing
lymphatic vessels of the myometrium and blood vessels
of the endometrium; no significant changes were
observed in the myometrial blood vessels.
Until relatively recently, it was necessary to conduct
detailed histological, ultrastructural or functional studies
to describe the distribution of lymphatic vessels. The
available techniques all have associated limitations and it
is not always possible to accurately differentiate lym-
phatic vessels from blood vessels or tissue spaces. Specific
lymphatic endothelial cell markers (including Lyve-1,
podoplanin and VEGFR-3) are now available enabling
detailed studies of lymphatic growth and function. In the
current study, we have used three markers (Lyve-1, podo-
planin, VEGFR-3) to examine the distribution of lym-
phatics in the mouse uterus. Our observation that the
majority of lymphatic vessel profiles positive for Lyve-1,
podoplanin and VEGFR-3 are situated within the myo-
metrium is consistent with several earlier detailed histo-
logical and functional studies in mice, rats, rabbits and
sheep [35-40]. In these studies, a well developed lym-
phatic vasculature was observed in the connective tissue
separating the two myometrial muscle regions with
smaller lymphatic capillaries extending into the longitu-
dinal and circular muscle layers. Most of these studies
report few lymphatic vessels in the endometrium. How-
ever, some studies report contrary results suggesting the
presence of extensive endometrial lymphatic capillaries
in mice and rats [35,40]. There have also been conflicting
results in studies using lymphatic-specific endothelial cell
markers. While Donoghue et al. [4] describe a distinct
population of lymphatic vessels in the human endome-
trium based on podoplanin (D2-40) immunohistochem-
Figure 3 Increased proliferation and surface area in myometrial 
lymphatic vessels in response to VEGF-D over-expression. Uterine 
horns of NOD SCID mice were inoculated with control or VEGF-D ex-
pressing 293EBNA cells. The density of myometrial lymphatic vessels 
(A) did not vary between mice treated with VEGF-D expressing cells rel-
ative to control cells. However, the percentage of myometrial lymphat-
ic vessels that contained proliferating cells (B) at sites adjacent to 
tumors was significantly increased in mice treated with VEGF-D cells, 
relative to control cells. Similarly, the surface area of myometrial lym-
phatic vessels (C) was significantly increased in sites adjacent to VEGF-
D expressing tumors relative to control tumours. Black bars: control 
cells; White bars: VEGF-D cells. Data are illustrated as means ± SEM (n = 
7-9). Groups that do not share a letter in common are significantly dif-
ferent (P < 0.05).
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Figure 4 Vasculature in uteri from NOD SCID mice inoculated with control or VEGF-2-expressing 293EBNA cells. Representative photomicro-
graphs of uterine horns from NOD SCID mice inoculated with control (A, C, E, G) or VEGF-D (B, D, F, H) expressing 293EBNA cells. (A, B) Myometrial 
lymphatic endothelial cell proliferation was increased in mice treated with VEGF-D expressing cells relative to those treated with control cells. Red: 
PCNA positive proliferating cells, Blue: Lyve-1 positive lymphatic vessel profiles. (C, D) Myometrial lymphatic vessels (white arrows). Note increased size 
of vessels in uterus exposed to VEGF-D. Brown: tumor cells (C: human mitochondrial positive cells, D: human VEGF-D positive cells). (E, F) There were 
also increased numbers of proliferating endometrial blood endothelial cells (adjacent to tumors) in mice treated with VEGF-D expressing cells relative 
to control cells. Red: PCNA positive proliferating cells, blue: CD31 positive blood vessel profiles. Black arrows: blood vessels. (G, H) Endometrial blood 
vessels (black arrows, note increased vessel size in uterus exposed to VEGF-D). Red: PCNA positive proliferating cells, blue: CD31 positive blood vessel 
profiles.
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lymphatics in the endometrium [33,34]. It is apparent
that caution is still required when examining lymphatic
vessels within uterine tissues, even when lymphatic
endothelial cell markers are used. In addition, it will be
important for future researchers to investigate the func-
tional differences in uterine vessel populations exhibiting
differential lymphatic-endothelial specific marker expres-
sion.
In this study, we used a VEGF-D over-expressing tumor
cell line as a model of VEGF-D over-expression in endo-
metrial cancer. We chose to use the 293EBNA-VEGF-D
cells as they had previously been shown to induce lymp-
hangiogenesis and angiogenesis in NOD/SCID mice [25].
In addition, the original 293EBNA cells do not express
detectable levels of VEGF-A, VEGF-C or VEGF-D,
Figure 5 Increased proliferation and surface area in endometrial 
blood vessels in response to VEGF-D over-expression. Uterine 
horns of NOD SCID mice were inoculated with control or VEGF-D ex-
pressing 293EBNA cells. The density of endometrial blood vessels (A) 
did not vary between mice treated with VEGF-expressing cells relative 
to control cells. However, the percentage of endometrial blood vessels 
that contained proliferating cells (B) at sites adjacent to tumors was 
significantly increased in mice treated with VEGF-D cells, relative to 
control cells. Similarly, the surface area of endometrial blood vessels (C) 
was significantly increased in sites adjacent to VEGF-D expressing tu-
mors relative to control tumours. Black bars: control cells; White bars: 
VEGF-D cells. Data are illustrated as means ± SEM (n = 7-9). Groups that 
do not share a letter in common are significantly different (P < 0.05).
Figure 6 No significant change in myometrial blood vessels in re-
sponse to VEGF-D over-expression. Uterine horns of NOD SCID mice 
were inoculated with control or VEGF-D expressing 293EBNA cells. The 
density of myometrial blood vessels (C) did not vary between mice 
treated with VEGF-expressing cells relative to control cells. There was 
also no significant difference in the percentage of myometrial blood 
vessels (B) that contained proliferating cells or the surface area of my-
ometrial blood vessels (C) in mice with VEGF-D expressing tumors rel-
ative to control tumours. Black bars: control cells; White bars: VEGF-D 
cells. Data are illustrated as means ± SEM (n = 7-9).
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ily members on our analyses. The 293EBNA-VEGF-D
cells express full-length VEGF-D (53 kD), some of which
is proteolytically processed to intermediate and fully pro-
cessed forms with higher affinities for its cognate recep-
tors VEGFR-2 and VEGFR-3 on endothelium. The VEGF-
D produced by these cells was previously shown to induce
tumor angiogenesis and lymphangiogenesis and to pro-
mote tumor metastasis to local lymph nodes when cells
were injected subcutaneously [25]. VEGF-D has also been
shown to induce lymphangiogenesis in several other
models following cell-mediated over-expression [25],
adenoviral delivery [41,42] and transgenic expression
[43].
Although the presence of VEGF-D-expressing
293EBNA tumor cells did not induce endometrial lymp-
hangiogenesis, they did cause differential effects on the
existing uterine vasculature. Increased proliferation and
vessel size was observed in the myometrial lymphatic and
endometrial blood vessels. Similar vessel enlargement has
been observed in rabbit and mouse hind limb [24,42], rat
cremaster muscle [41], pig heart [44] and mouse skin [43]
in response to VEGF-D. In contrast, no significant
changes were noted in the myometrial blood vessels. This
differential response to VEGF-D might be due to differ-
ences in the local tissue microenvironment or the partic-
ular response of these tissue-specific vessels. Adenoviral
VEGF-D (AdvVEGF-D) over-expression in mouse skin
induces increased angiogenesis and lymphangiogenesis
with vessel enlargement [41,42], while in the lung Adv-
VEGF-D induces lymphangiogenesis without angiogene-
sis [45]. Alternatively, the differential responses may
reflect the location of blood or lymph vessels on the vas-
cular tree. The small endometrial capillaries, which have
less mural cell (pericytes and vascular smooth muscle
cells) support than the more stable blood arterioles pres-
ent in the connective tissue of the myometrium [1], are
likely to be more responsive to angiogenic promoters.
However, this latter hypothesis does not explain the lack
of response in small capillaries present within the muscle
itself.
It has been proposed that VEGF-D is crucial to carci-
noma-associated lymphangiogenesis, as well as the pro-
cess of metastasis [12,25]. In the current study, 293-
EBNA-VEGF-D cells or tumor emboli were observed
within myometrial lymphatic vessels. In contrast, no
invasion of lymphatic vessels was observed in mice
receiving control 293EBNA cells. The presence of emboli
in the vasculature is a prognostic factor in several can-
cers, including endometrial cancer (see [8,46,47] and ref-
erences therein). Invasion of the vasculature is also
thought to be an early step in the metastatic process. The
Figure 7 VEGF-D expressing 293EBNA cells invade uterine lym-
phatic vessels. Uterine horns of NOD SCID mice were inoculated with 
control or VEGF-D expressing 293EBNA cells. (A) Control tumor cells 
(brown) did not invade uterine blood or lymphatic (blue) vessels; how-
ever, (B-D) examples of myometrial lymphatic vessels containing tu-
mor cells were observed in all mice treated with VEGF-D expressing 
cells. Note the tumor cells in a lymphatic vessel adjacent to unaffected 
blood vessels in B and C. Note the large tumor emboli in the distorted 
lymphatic vessel in D. (A and B: brown: tumor cells; C and D; blue: lym-
phatic vessels, brown: PCNA positive proliferating cells). Heavy black 
arrow: tumor cells. Fine black arrows: blood vessel. White arrow: lym-
phatic vessel.
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invasion and ultimately metastasis is not known.
Although VEGF-D over-expression caused enlargement
and proliferation of uterine lymphatic vessels, these
effects in themselves are not sufficient to explain the
observed migration of tumor cells into uterine vessels.
Future research will be needed to determine whether ves-
sel invasion reflects characteristics of the endometrial
VEGF-D expressing tumor cells or because of changes
induced in the vessels affected.
In addition to our focus on endometrial cancer, the
observed effects of VEGF-D over-expression on uterine
vasculature raises questions about the function of this
growth factor in normal uterine remodelling. In this
study, no new growth of lymphatic vessels into the endo-
metrium was induced. A possible explanation for this
lack of growth is that lymphangiogenesis is actively inhib-
ited within the endometrium. Such inhibition has been
observed in the cornea, which must remain avascular to
maintain the transparency required for vision. It has been
shown that constitutive expression of VEGFR-3 on the
corneal epithelium acts as a sink for VEGFR-3 ligands,
thereby suppressing vascular growth into the cornea [48].
In addition, a recent study has identified a soluble splice
variant of VEGFR-2 in mice that inhibits lymphangiogen-
esis by blocking VEGF-C. This isoform specifically blocks
injury-induced lymphangiogenesis, but not hemangio-
genesis, in the mouse cornea [49]. Several studies have
described varying amounts of non-lymphatic VEGFR-3
immunostaining within the endometrial epithelium and
stroma [50-52], however, the activity of this non-lym-
phatic VEGFR-3 remains to be elucidated. Whether a sol-
uble isoform of VEGFR-2 is expressed in the uterus has
not yet been investigated.
In the current study, mouse uterus was treated with
human VEGF-D which interacts with both mouse and
human VEGFR-2 and VEGFR-3. It should be noted, how-
ever, that mouse VEGF-D does not bind with VEGFR-2
[21] and it is unlikely that similar blood vessel responses
would have been observed if tumour cells had been trans-
fected with mouse VEGF-D. However, as human VEGF-
D does bind with human VEGFR-2, future studies need to
address the functional role of VEGF-D in human endo-
metrium with emphasis on the differential effects on dif-
ferent vascular components within the tissue.
Future studies should also consider the role of VEGF-C
in endometrial vascular remodeling. As with VEGF-D,
VEGF-C can interact with both VEGFR-2 and VEGFR-3,
and has been shown to induce both angiogenesis and
lymphangiogenesis in various tissue and pathology mod-
els [53-55]. Depending on the nature of the ligand and the
presence of co-receptors, the VEGF receptors can form
both homo and heterodimers with subsequent auto-
phosphorylation of the receptor complex and down-
stream signaling; the associated variation in signaling
pathways associated with homo versus heterodimers has
yet to be elucidated (reviewed in [56,57]). The specific
interactions of VEGF-D with VEGF receptors has not
been examined in the current model, but future research
in this area will highlight the mechanisms by which
VEGF-D acts to promote lymphangiogenesis and metas-
tasis in endometrial cancer. While this study has focused
on the effects of VEGF-D overexpression on vessel mor-
phology and endothelial cell proliferation, future research
will need to consider the other processes influenced by
VEGF receptor activation (cell survival, cell migration,
vessel permeability). Modification of any of these pro-
cesses would also likely contribute to VEGF-D's role in
endometrial cancer progression.
The NOD SCID mice used in the current study have
various defects of immune function including decreased
numbers of circulating T lymphocytes, B lymphocytes
and natural killer cells. This means that any effects of
VEGF-D overexpression on the uterine lymphocyte pop-
ulation could not be investigated in this model. The pro-
files of VEGF-D and VEGFR-3 expression may also vary
in the uterus of these mice relative to those in the C57/
CBA mice used for the initial analysis. Despite the above,
our study has shown a clear effect of VEGF-D over-
expression on uterine vasculature.
Conclusions
In conclusion, we have shown that lymphatic vessels pos-
itive for key lymphatic specific markers Lyve-1, podopla-
nin and VEGFR-3 are largely restricted to the
myometrium in the mouse uterus. We have also demon-
strated in a model of endometrial cancer, that VEGF-D
over-expressing tumor cells do not stimulate growth of
lymphatic vessels into the endometrium. This may be due
to a lack of appropriate small lymphatic vessels/capillaries
in the uterus on which VEGF-D can act. Alternatively, an
inhibitor(s) preventing lymphangiogenesis may be pres-
ent within the endometrium. Although no endometrial
lymphangiogenesis was observed, VEGF-D over-expres-
sion did stimulate proliferation and an increase in the size
of existing uterine vasculature. VEGF-D expressing
tumor cells were also observed within myometrial lym-
phatic vessels; whether this vascular invasion reflects
characteristics of the VEGF-D tumor cells or induced-
changes in the uterine vasculature remain to be eluci-
dated.
The results obtained in the current study show that
VEGF-D over-expression has differential effects on the
uterine vasculature. These effects may facilitate VEGF-
D's ability to promote endometrial cancer metastasis and
disease progression. The results also highlight the utility
of the current model as a tool to investigate endometrial
carcinoma-associated VEGF-D expression and activity.
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